Quantitation of melatonin and n-acetylserotonin in human plasma by nanoflow LC-MS/MS and electrospray LC-MS/MS

Journal of Mass Spectrometry

Volumn 47, Issue 3, 2012, Pages 277-285

  Carter, Melissa D ^a   Wade Calcutt, M ^a   Malow, Beth A ^a   Rose, Kristie L ^a   Hachey, David L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

autism spectrum disorder; Melatonin; N acetylserotonin; Nanoflow LC MS MS

Indexed keywords

AUTISM SPECTRUM DISORDERS; BLOOD SAMPLES; CHEMICAL PRECURSORS; CHILDREN WITH AUTISMS; DOSING STRATEGY; DYNAMIC RANGE; ELECTROSPRAYS; ENDOGENOUS LEVEL; FUSED-SILICA CAPILLARIES; HIGHLY SENSITIVE; HUMAN PLASMAS; INTERNAL STANDARDS; LC-MS/MS; MELATONIN; MEMBRANE DIALYSIS; N-ACETYLSEROTONIN; NANOFLOWS; NANOSPRAY; PEDIATRIC PATIENTS; PLASMA SAMPLES;

CENTRIFUGATION; DIALYSIS; DIALYSIS MEMBRANES; DISEASES; ELECTROSPRAY IONIZATION; FUSED SILICA; PLASMA (HUMAN); POLYIMIDES;

HORMONES;

MELATONIN; N ACETYLSEROTONIN; NATROL; POLYIMIDE; SILICON DIOXIDE; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AREA UNDER THE CURVE; ARTICLE; AUTISM; BLOOD ANALYSIS; CHEMICAL STRUCTURE; CHILD; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; PLASMA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SENSITIVITY ANALYSIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MELATONIN; NANOTECHNOLOGY; REPRODUCIBILITY OF RESULTS; SEROTONIN; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY;

EID: 84859086985     PISSN: 10765174     EISSN: 10969888     Source Type: Journal    
DOI: 10.1002/jms.2051     Document Type: Article

References (21)

1. G. A. Bubenik, S. J. Konturek,. Melatonin and aging: prospects for human treatment. J. Physiol. Pharmacol. 2011, 62, 13.
2. M. Wilhelmsen, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011.
3. A. Ulugol, et al. Antihyperalgesic, but not antiallodynic, effect of melatonin in nerve-injured neuropathic mice: possible involvements of the L-arginine-NO pathway and opioid system. Life Sci. 2006, 78, 1592.
4. T. Wang, et al. Effects of melatonin on orphanin FQ/nociceptin-induced hyperalgesia in mice. Brain Res 2006, 1085, 43.
5. D. A. Rossignol, R. E. Frye,. Melatonin in autism spectrum disorders: a systematic review and meta-analysis. Dev Med Child Neurol 2011, 53, 783.
6. G. Kulman, et al. Evidence of pineal endocrine hypofunction in autistic children. Neuro Endocrinol Lett 2000, 21, 31.
7. J. Melke, et al. Abnormal melatonin synthesis in autism spectrum disorders. Mol Psychiatry 2008, 13, 90.
8. I. Nir, et al. Brief report: circadian melatonin, thyroid-stimulating hormone, prolactin, and cortisol levels in serum of young adults with autism. J Autism Dev Disord 1995, 25, 641.
9. S. Tordjman, et al. Nocturnal excretion of 6-sulphatoxymelatonin in children and adolescents with autistic disorder. Biol. Psychiatry 2005, 57, 134.
10. R. M. Leu, et al. Relation of melatonin to sleep architecture in children with autism. J Autism Dev Disord 2011, 41, 427.
11. G. M. Anderson,. Genetics of childhood disorders: XLV. Autism, part 4: serotonin in autism. J Am Acad Child Adolesc Psychiatry 2002, 41, 1513.
12. K. S. Reddy,. Cytogenetic abnormalities and fragile-X syndrome in Autism Spectrum Disorder. BMC Med Genet 2005, 6, 3.
13. E. A. de Almeida, et al. Measurement of melatonin in body fluids: standards, protocols and procedures. Childs Nerv Syst 2011, 27, 879.
14. B. C. Koch, et al. Circadian sleep-wake rhythm disturbances in end-stage renal disease. Nat. Rev. Nephrol. 2009, 5, 407.
15. J. B. Shear, et al. Determination of fluorogen-labeled neurotransmitters at the zeptomole level using two photon excited fluorescence with capillary electrophoresis. Anal. Chem. 1998, 70, 3470.
16. G. Chen, et al. Melatonin in Chinese medicinal herbs. Life Sci. 2003, 73, 19.
17. G. Simonin, et al. Determination of melatonin in biological fluids in the presence of the melatonin agonist S 20098: comparison of immunological techniques and GC-MS methods. J. Pharm. Biomed. Anal. 1999, 21, 591.
18. V. Rizzo, et al. Determination of free and total (free plus protein-bound) melatonin in plasma and cerebrospinal fluid by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 774, 17.
19. E. Gilad, N. Zisapel,. High-affinity binding of melatonin to hemoglobin. Biochem Mol Med 1995, 56, 115.
20. A. Cavallo, W. A. Ritschel,. Pharmacokinetics of melatonin in human sexual maturation. J. Clin. Endocrinol. Metab. 1996, 81, 1882.
21. B. A. Malow, K. W. Adkins, S. G. McGrew, L. Wang, S. E. Goldman, D. Fawkes, C. Burnette,. Melatonin for sleep in children with autism: A controlled trial examining dose, tolerability, and outcomes. J. Autism Dev. Disord. 2011 Dec. 10 (Epub ahead of print).